Gene expression in lung and liver after intravenous infusion of polyethylenimine complexes of Sleeping Beauty transposons

Kelly M. Podetz-Pedersen, Jason B. Bell, Terry W.J. Steele, Andrew Wilber, W. Thomas Shier, Lalitha Belur, R S Mc Ivor, Perry B Hackett

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

Two methods of systemic gene delivery have been extensively explored, using the mouse as a model system: hydrodynamic delivery, wherein a DNA solution equivalent in volume to 10% of the mouse weight is injected intravenously in less than 10 sec, and condensation of DNA with polyethylenimine (PEI) for standard intravenous infusion. Our goal in this study was to evaluate quantitatively the kinetics of gene expression, using these two methods for delivery of Sleeping Beauty transposons. Transposons carrying a luciferase expression cassette were injected into mice either hydrodynamically or after condensation with PEI at a PEI nitrogen-to-DNA phosphate ratio of 7. Gene expression in the lungs and liver after hydrodynamic delivery resulted in exponential decay with a half-life of about 35-40 hr between days 1 and 14 postinjection. The decay kinetics of gene expression after PEI-mediated gene delivery were more complex; an initial decay rate of 6 hr was followed by a more gradual loss of activity. Consequently, the liver became the primary site of gene expression about 4 days after injection of PEI-DNA, and by 14 days expression in the liver was 10-fold higher than in the lung. Overall levels of gene expression 2 weeks postinjection were 100-to 1000-fold lower after PEI-mediated delivery compared with hydrodynamic injection. These results provide insight into the relative effectiveness and organ specificity of these two methods of nonviral gene delivery when coupled with the Sleeping Beauty transposon system.

Original languageEnglish (US)
Pages (from-to)210-220
Number of pages11
JournalHuman gene therapy
Volume21
Issue number2
DOIs
StatePublished - Feb 1 2010

Fingerprint

Polyethyleneimine
Beauty
Intravenous Infusions
Gene Expression
Lung
Liver
Hydrodynamics
DNA
Genes
Organ Specificity
Injections
Luciferases
Half-Life
Nitrogen
Phosphates
Weights and Measures

Cite this

Gene expression in lung and liver after intravenous infusion of polyethylenimine complexes of Sleeping Beauty transposons. / Podetz-Pedersen, Kelly M.; Bell, Jason B.; Steele, Terry W.J.; Wilber, Andrew; Shier, W. Thomas; Belur, Lalitha; Mc Ivor, R S; Hackett, Perry B.

In: Human gene therapy, Vol. 21, No. 2, 01.02.2010, p. 210-220.

Research output: Contribution to journalArticle

@article{288af241f0274bc083751f4df7fc0341,
title = "Gene expression in lung and liver after intravenous infusion of polyethylenimine complexes of Sleeping Beauty transposons",
abstract = "Two methods of systemic gene delivery have been extensively explored, using the mouse as a model system: hydrodynamic delivery, wherein a DNA solution equivalent in volume to 10{\%} of the mouse weight is injected intravenously in less than 10 sec, and condensation of DNA with polyethylenimine (PEI) for standard intravenous infusion. Our goal in this study was to evaluate quantitatively the kinetics of gene expression, using these two methods for delivery of Sleeping Beauty transposons. Transposons carrying a luciferase expression cassette were injected into mice either hydrodynamically or after condensation with PEI at a PEI nitrogen-to-DNA phosphate ratio of 7. Gene expression in the lungs and liver after hydrodynamic delivery resulted in exponential decay with a half-life of about 35-40 hr between days 1 and 14 postinjection. The decay kinetics of gene expression after PEI-mediated gene delivery were more complex; an initial decay rate of 6 hr was followed by a more gradual loss of activity. Consequently, the liver became the primary site of gene expression about 4 days after injection of PEI-DNA, and by 14 days expression in the liver was 10-fold higher than in the lung. Overall levels of gene expression 2 weeks postinjection were 100-to 1000-fold lower after PEI-mediated delivery compared with hydrodynamic injection. These results provide insight into the relative effectiveness and organ specificity of these two methods of nonviral gene delivery when coupled with the Sleeping Beauty transposon system.",
author = "Podetz-Pedersen, {Kelly M.} and Bell, {Jason B.} and Steele, {Terry W.J.} and Andrew Wilber and Shier, {W. Thomas} and Lalitha Belur and {Mc Ivor}, {R S} and Hackett, {Perry B}",
year = "2010",
month = "2",
day = "1",
doi = "10.1089/hum.2009.128",
language = "English (US)",
volume = "21",
pages = "210--220",
journal = "Human Gene Therapy",
issn = "1043-0342",
publisher = "Mary Ann Liebert Inc.",
number = "2",

}

TY - JOUR

T1 - Gene expression in lung and liver after intravenous infusion of polyethylenimine complexes of Sleeping Beauty transposons

AU - Podetz-Pedersen, Kelly M.

AU - Bell, Jason B.

AU - Steele, Terry W.J.

AU - Wilber, Andrew

AU - Shier, W. Thomas

AU - Belur, Lalitha

AU - Mc Ivor, R S

AU - Hackett, Perry B

PY - 2010/2/1

Y1 - 2010/2/1

N2 - Two methods of systemic gene delivery have been extensively explored, using the mouse as a model system: hydrodynamic delivery, wherein a DNA solution equivalent in volume to 10% of the mouse weight is injected intravenously in less than 10 sec, and condensation of DNA with polyethylenimine (PEI) for standard intravenous infusion. Our goal in this study was to evaluate quantitatively the kinetics of gene expression, using these two methods for delivery of Sleeping Beauty transposons. Transposons carrying a luciferase expression cassette were injected into mice either hydrodynamically or after condensation with PEI at a PEI nitrogen-to-DNA phosphate ratio of 7. Gene expression in the lungs and liver after hydrodynamic delivery resulted in exponential decay with a half-life of about 35-40 hr between days 1 and 14 postinjection. The decay kinetics of gene expression after PEI-mediated gene delivery were more complex; an initial decay rate of 6 hr was followed by a more gradual loss of activity. Consequently, the liver became the primary site of gene expression about 4 days after injection of PEI-DNA, and by 14 days expression in the liver was 10-fold higher than in the lung. Overall levels of gene expression 2 weeks postinjection were 100-to 1000-fold lower after PEI-mediated delivery compared with hydrodynamic injection. These results provide insight into the relative effectiveness and organ specificity of these two methods of nonviral gene delivery when coupled with the Sleeping Beauty transposon system.

AB - Two methods of systemic gene delivery have been extensively explored, using the mouse as a model system: hydrodynamic delivery, wherein a DNA solution equivalent in volume to 10% of the mouse weight is injected intravenously in less than 10 sec, and condensation of DNA with polyethylenimine (PEI) for standard intravenous infusion. Our goal in this study was to evaluate quantitatively the kinetics of gene expression, using these two methods for delivery of Sleeping Beauty transposons. Transposons carrying a luciferase expression cassette were injected into mice either hydrodynamically or after condensation with PEI at a PEI nitrogen-to-DNA phosphate ratio of 7. Gene expression in the lungs and liver after hydrodynamic delivery resulted in exponential decay with a half-life of about 35-40 hr between days 1 and 14 postinjection. The decay kinetics of gene expression after PEI-mediated gene delivery were more complex; an initial decay rate of 6 hr was followed by a more gradual loss of activity. Consequently, the liver became the primary site of gene expression about 4 days after injection of PEI-DNA, and by 14 days expression in the liver was 10-fold higher than in the lung. Overall levels of gene expression 2 weeks postinjection were 100-to 1000-fold lower after PEI-mediated delivery compared with hydrodynamic injection. These results provide insight into the relative effectiveness and organ specificity of these two methods of nonviral gene delivery when coupled with the Sleeping Beauty transposon system.

UR - http://www.scopus.com/inward/record.url?scp=77249179341&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77249179341&partnerID=8YFLogxK

U2 - 10.1089/hum.2009.128

DO - 10.1089/hum.2009.128

M3 - Article

C2 - 19761403

AN - SCOPUS:77249179341

VL - 21

SP - 210

EP - 220

JO - Human Gene Therapy

JF - Human Gene Therapy

SN - 1043-0342

IS - 2

ER -